Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1B | P49286 | 2/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.59 |
| ▸ | MAPT | P10636 | 3/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | NPC1 | O15118 | 3/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | FAAH | O00519 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 3/20 | 0.54 |
| ▸ | RAB9A | P51151 | 3/20 | 0.54 |
| ▸ | CRHBP | P24387 | 1/20 | 0.54 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Desmedipham SCHEMBL725936 | 0.92 | MAPT (0.59) | MTNR1BMAPK1MAPTHSD17B10LMNA | |
| Desmedipham SCHEMBL29516752 | 0.86 | MAPK1 (0.68) | MTNR1BMAPK1MAPTHSD17B10LMNA | |
| SCHEMBL11511906 | 0.86 | MTNR1B (0.60) | MTNR1BMAPK1MAPTHSD17B10LMNA | |
| Desmedipham SCHEMBL4895813 | 0.86 | MAPK1 (0.68) | MTNR1BMAPK1MAPTHSD17B10LMNA | |
| Desmedipham SCHEMBL55084 | 0.86 | MAPK1 (0.68) | MTNR1BMAPK1MAPTHSD17B10LMNA | |
| SCHEMBL13620569 | 0.85 | ALDH1A1 (0.68) | MAPK1LMNAALDH1A1NPC1HTT | |
| SCHEMBL134424 | 0.84 | MAPK1 (0.77) | MTNR1BMAPK1MAPTHSD17B10LMNA | |
| SCHEMBL29512574 | 0.84 | MAPK1 (0.77) | MTNR1BMAPK1MAPTHSD17B10LMNA | |
| SCHEMBL6647977 | 0.84 | MTNR1B (0.82) | MTNR1BMAPK1MAPTHSD17B10LMNA | |
| SCHEMBL7565149 | 0.83 | MAPK1 (0.81) | MTNR1BMAPK1MAPTHSD17B10LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090259062-A1 | SURFACTANT COMPOSITIONS AND ASSOCIATED METHOD | MOMENTIVE PERFORMANCE MATERIALS INC. | 2009-10-15 | — | — | US | disclosed |
| US-7601680-B2 | Gemini silicone surfactant compositions and associated methods | MOMENTIVE PERFORMANCE MATERIALS (US) | 2009-10-13 | — | — | US | disclosed |
| US-20070134283-A1 | Surfactant-based composition and associated methods | GENERAL ELECTRIC COMPANY (US) | 2007-06-14 | — | — | US | disclosed |
| US-20070135329-A1 | Surfactant compositions and associated method | GENERAL ELECTRIC COMPANY (US) | 2007-06-14 | — | — | US | disclosed |
| CN-1040367-A | Heterogeneous ring compound | ICI PLC (GB) | 1990-03-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090259062-A1 | SURFACTANT COMPOSITIONS AND ASSOCIATED METHOD | SGMS2, SGMS1, GMNN | MTNR1B 4342/4885MAPK1 4729/4885MAPT 3690/4885 |
| US-20070134283-A1 | Surfactant-based composition and associated methods | SGMS2, SGMS1, GEMIN4 | MTNR1B 4758/4885MAPK1 4781/4885MAPT 2635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.